<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00492557</url>
  </required_header>
  <id_info>
    <org_study_id>6115A1-3008</org_study_id>
    <nct_id>NCT00492557</nct_id>
  </id_info>
  <brief_title>Study Evaluating Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine With Influenza Vaccine in Adults</brief_title>
  <official_title>A Phase 3, Randomized, Double-blind Trial to Evaluate Safety, Tolerability, and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine When Administered Concomitantly With Trivalent Inactivated Influenza Vaccine in Healthy Adults 65 Years of Age or Older, Who Are Naive to 23-Valent Pneumococcal Polysaccharide Vaccine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The 13-valent pneumococcal conjugate vaccine (13vPnC) is being developed for adults to
      prevent pneumococcal diseases such as meningitis (inflammation of the brain lining),
      septicemia (blood poisoning), and pneumonia (inflammation of the lungs). As trivalent
      influenza vaccine (TIV) is frequently given to adults, it is important to show that both
      vaccines can safely be given together without affecting the immune response (body's ability
      to protect against disease).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TIV Comparisons: Percentage of Participants Achieving at Least a 4-fold Increase in the Titer of the Standard Hemagglutination Inhibition Assay (HAI)</measure>
    <time_frame>Baseline and 1 month after TIV vaccination</time_frame>
    <description>Percentage of participants achieving at least a 4-fold increase in the titer of the standard HAI for each influenza virus subtype (A/H1N1, A/H3N2, and B) were compared.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>13vPnC Comparisons: Serotype-specific Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentration (GMC)</measure>
    <time_frame>1 month after 13vPnC vaccination</time_frame>
    <description>IgG GMC as measured by enzyme-linked immunosorbent assay (ELISA) and expressed in micrograms per mL (mcg/mL) for serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1185</enrollment>
  <condition>Pneumococcal Infections</condition>
  <arm_group>
    <arm_group_label>13vPnC+TIV Followed by Placebo 1 month later</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo+TIV Followed by 13vPnC 1 month later</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>13-valent pneumococcal conjugate vaccine</intervention_name>
    <description>Single 0.5 milliliter (mL) 13-valent pneumococcal conjugate vaccine (13vPnC) and a single 0.5 mL trivalent inactivated influenza vaccine (TIV), administered intramuscularly (IM), followed by a single 0.5 mL vaccine 13vPnC placebo, 1 month later.</description>
    <arm_group_label>13vPnC+TIV Followed by Placebo 1 month later</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>13vPnC + TIV</intervention_name>
    <description>Single 0.5 mL 13vPnC placebo vaccine and a single 0.5 mL TIV, administered IM, followed by a single 0.5 mL 13vPnC vaccine, 1 month later.</description>
    <arm_group_label>Placebo+TIV Followed by 13vPnC 1 month later</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Generally healthy male or female adults 65 years of age or older.

          -  Available for the duration of the trial - approximately 2 months.

          -  No previous vaccination with any pneumococcal vaccine.

          -  No history of severe adverse reaction associated with a vaccine.

          -  No allergy to egg proteins (eggs or egg products) and chicken proteins.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Wyeth is now a wholly owned subsidiary of Pfizer</affiliation>
  </overall_official>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2007</study_first_submitted>
  <study_first_submitted_qc>June 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2007</study_first_posted>
  <results_first_submitted>January 17, 2012</results_first_submitted>
  <results_first_submitted_qc>January 17, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 17, 2012</results_first_posted>
  <disposition_first_submitted>January 21, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>September 24, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 28, 2009</disposition_first_posted>
  <last_update_submitted>January 17, 2012</last_update_submitted>
  <last_update_submitted_qc>January 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pneumococcal Disease</keyword>
  <keyword>Pneumococcal Conjugate Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 1185 participants were enrolled, of which 1160 were randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>13vPnC+TIV Followed by Placebo 1 Month Later</title>
          <description>Single 0.5 milliliter (mL) 13-valent pneumococcal conjugate vaccine (13vPnC) and a single 0.5 mL trivalent inactivated influenza vaccine (TIV), administered intramuscularly (IM), followed by a single 0.5 mL 13vPnC placebo vaccine, 1 month later.</description>
        </group>
        <group group_id="P2">
          <title>Placebo+TIV Followed by 13vPnC 1 Month Later</title>
          <description>Single 0.5 mL 13vPnC placebo vaccine and a single 0.5 mL TIV, administered IM, followed by a single 0.5 mL 13vPnC, 1 month later.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="580"/>
                <participants group_id="P2" count="580"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated Dose 1</title>
              <participants_list>
                <participants group_id="P1" count="577"/>
                <participants group_id="P2" count="575"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated Dose 2</title>
              <participants_list>
                <participants group_id="P1" count="560"/>
                <participants group_id="P2" count="558"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="556"/>
                <participants group_id="P2" count="557"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Subject request</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failed to return</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>13vPnC+TIV Followed by Placebo 1 Month Later</title>
          <description>Single 0.5 milliliter (mL) 13-valent pneumococcal conjugate vaccine (13vPnC) and a single 0.5 mL trivalent inactivated influenza vaccine (TIV), administered intramuscularly (IM), followed by a single 0.5 mL 13vPnC placebo vaccine, 1 month later.</description>
        </group>
        <group group_id="B2">
          <title>Placebo+TIV Followed by 13vPnC 1 Month Later</title>
          <description>Single 0.5 mL 13vPnC placebo vaccine and a single 0.5 mL TIV, administered IM, followed by a single 0.5 mL 13vPnC, 1 month later.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="576"/>
            <count group_id="B2" value="575"/>
            <count group_id="B3" value="1151"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Data for participants in the safety population (ie. those who received at least 1 dose of study vaccine) are presented. The number of participants equals the number receiving Dose 1 in the Participant Flow section (1152), minus 1 participant in the &quot;13vPnC+TIV followed by placebo 1 month later&quot; group who received a regimen that was not part of the study.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.1" spread="5.6"/>
                    <measurement group_id="B2" value="72.1" spread="5.5"/>
                    <measurement group_id="B3" value="72.1" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Data for participants in the safety population (ie. those who received at least 1 dose of study vaccine) are presented. The number of participants equals the number receiving Dose 1 in the Participant Flow section (1152), minus 1 participant in the &quot;13vPnC+TIV followed by placebo 1 month later&quot; group who received a regimen that was not part of the study.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="289"/>
                    <measurement group_id="B2" value="290"/>
                    <measurement group_id="B3" value="579"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="287"/>
                    <measurement group_id="B2" value="285"/>
                    <measurement group_id="B3" value="572"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>TIV Comparisons: Percentage of Participants Achieving at Least a 4-fold Increase in the Titer of the Standard Hemagglutination Inhibition Assay (HAI)</title>
        <description>Percentage of participants achieving at least a 4-fold increase in the titer of the standard HAI for each influenza virus subtype (A/H1N1, A/H3N2, and B) were compared.</description>
        <time_frame>Baseline and 1 month after TIV vaccination</time_frame>
        <population>Evaluable immunogenicity population: had participants who adhered to protocol requirements, had valid and determinate assay results, and had no major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC+TIV</title>
            <description>Single 0.5 milliliter (mL) 13-valent pneumococcal conjugate vaccine (13vPnC) and a single 0.5 mL trivalent inactivated influenza vaccine (TIV), administered intramuscularly (IM).</description>
          </group>
          <group group_id="O2">
            <title>Placebo+TIV</title>
            <description>Single 0.5 mL 13vPnC placebo vaccine and a single 0.5 mL TIV, administered IM.</description>
          </group>
        </group_list>
        <measure>
          <title>TIV Comparisons: Percentage of Participants Achieving at Least a 4-fold Increase in the Titer of the Standard Hemagglutination Inhibition Assay (HAI)</title>
          <description>Percentage of participants achieving at least a 4-fold increase in the titer of the standard HAI for each influenza virus subtype (A/H1N1, A/H3N2, and B) were compared.</description>
          <population>Evaluable immunogenicity population: had participants who adhered to protocol requirements, had valid and determinate assay results, and had no major protocol violations.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="549"/>
                <count group_id="O2" value="547"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Influenza virus subtype: A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.3" lower_limit="76.7" upper_limit="83.5"/>
                    <measurement group_id="O2" value="78.6" lower_limit="74.9" upper_limit="81.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza virus subtype: A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.0" lower_limit="53.7" upper_limit="62.2"/>
                    <measurement group_id="O2" value="62.6" lower_limit="58.4" upper_limit="66.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza virus subtype: B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.2" lower_limit="47.9" upper_limit="56.4"/>
                    <measurement group_id="O2" value="54.0" lower_limit="49.7" upper_limit="58.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Influenza virus subtype: A/H1N1. Primary null hypothesis for each of the influenza virus subtypes is: proportion of participants achieving a 4-fold increase in titer when 13vPnC+TIV were administered concomitantly, minus the proportion of participants achieving a 4-fold increase in titer when TIV was administered alone (with placebo) &lt;= -0.10.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for a given virus subtype was demonstrated if the lower bound of the 2-sided, 95% confidence interval (CI), computed using the Chan and Zhang procedure, for the difference in proportions (13vPnC+TIV – TIV alone) was greater than –0.10.</non_inferiority_desc>
            <param_type>Percent Difference</param_type>
            <param_value>1.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.1</ci_lower_limit>
            <ci_upper_limit>6.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Influenza virus subtype: A/H3N2. Primary null hypothesis for each of the influenza virus subtypes is: proportion of participants achieving a 4-fold increase in titer when 13vPnC+TIV were administered concomitantly, minus the proportion of participants achieving a 4-fold increase in titer when TIV was administered alone (with placebo) &lt;= -0.10.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for a given virus subtype was demonstrated if the lower bound of the 2-sided, 95% CI, computed using the Chan and Zhang procedure, for the difference in proportions (13vPnC+TIV – TIV alone) was greater than –0.10.</non_inferiority_desc>
            <param_type>Percent Difference</param_type>
            <param_value>-4.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.4</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Influenza virus subtype: B. Primary null hypothesis for each of the influenza virus subtypes is: proportion of participants achieving a 4-fold increase in titer when 13vPnC+TIV were administered concomitantly, minus the proportion of participants achieving a 4-fold increase in titer when TIV was administered alone (with placebo) &lt;= -0.10.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for a given virus subtype was demonstrated if the lower bound of the 2-sided, 95% CI, computed using the Chan and Zhang procedure, for the difference in proportions (13vPnC+TIV – TIV alone) was greater than –0.10.</non_inferiority_desc>
            <param_type>Percent Difference</param_type>
            <param_value>-1.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.8</ci_lower_limit>
            <ci_upper_limit>4.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>13vPnC Comparisons: Serotype-specific Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentration (GMC)</title>
        <description>IgG GMC as measured by enzyme-linked immunosorbent assay (ELISA) and expressed in micrograms per mL (mcg/mL) for serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F.</description>
        <time_frame>1 month after 13vPnC vaccination</time_frame>
        <population>Evaluable immunogenicity population: had participants who adhered to protocol requirements, had valid and determinate assay results, and had no major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC+TIV</title>
            <description>Single 0.5 milliliter (mL) 13-valent pneumococcal conjugate vaccine (13vPnC) and a single 0.5 mL trivalent inactivated influenza vaccine (TIV), administered intramuscularly (IM).</description>
          </group>
          <group group_id="O2">
            <title>13vPnC</title>
            <description>Single 0.5 mL 13vPnC (administered 1 month after single 0.5 mL 13vPnC placebo vaccine and a single 0.5 mL TIV, IM).</description>
          </group>
        </group_list>
        <measure>
          <title>13vPnC Comparisons: Serotype-specific Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentration (GMC)</title>
          <description>IgG GMC as measured by enzyme-linked immunosorbent assay (ELISA) and expressed in micrograms per mL (mcg/mL) for serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F.</description>
          <population>Evaluable immunogenicity population: had participants who adhered to protocol requirements, had valid and determinate assay results, and had no major protocol violations.</population>
          <units>mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="549"/>
                <count group_id="O2" value="547"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.52" lower_limit="2.07" upper_limit="3.06"/>
                    <measurement group_id="O2" value="3.20" lower_limit="2.61" upper_limit="3.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.08" lower_limit="0.94" upper_limit="1.24"/>
                    <measurement group_id="O2" value="1.15" lower_limit="1.01" upper_limit="1.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.15" lower_limit="1.79" upper_limit="2.60"/>
                    <measurement group_id="O2" value="3.24" lower_limit="2.65" upper_limit="3.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.74" lower_limit="4.08" upper_limit="5.50"/>
                    <measurement group_id="O2" value="6.90" lower_limit="5.87" upper_limit="8.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.61" lower_limit="4.00" upper_limit="5.31"/>
                    <measurement group_id="O2" value="6.10" lower_limit="5.13" upper_limit="7.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.24" lower_limit="5.27" upper_limit="7.39"/>
                    <measurement group_id="O2" value="6.43" lower_limit="5.33" upper_limit="7.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.63" lower_limit="6.50" upper_limit="8.96"/>
                    <measurement group_id="O2" value="9.04" lower_limit="7.58" upper_limit="10.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.97" lower_limit="4.19" upper_limit="5.91"/>
                    <measurement group_id="O2" value="6.21" lower_limit="5.27" upper_limit="7.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.95" lower_limit="7.33" upper_limit="10.95"/>
                    <measurement group_id="O2" value="12.44" lower_limit="9.94" upper_limit="15.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.88" lower_limit="7.55" upper_limit="10.45"/>
                    <measurement group_id="O2" value="11.07" lower_limit="9.40" upper_limit="13.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.93" lower_limit="10.23" upper_limit="13.92"/>
                    <measurement group_id="O2" value="17.10" lower_limit="14.54" upper_limit="20.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.78" lower_limit="4.00" upper_limit="5.71"/>
                    <measurement group_id="O2" value="7.39" lower_limit="6.02" upper_limit="9.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.82" lower_limit="4.74" upper_limit="7.14"/>
                    <measurement group_id="O2" value="6.11" lower_limit="4.97" upper_limit="7.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 1. The primary null hypothesis was: the log of the GMC in the group receiving 13vPnC and TIV concomitantly, minus the log of the GMC in the group receiving 13vPnC alone (1 month after TIV) &lt;= -0.693.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The criterion upon which to declare non-inferiority was the lower bound of the 2-sided, 95% CI for the geometric mean ratio greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio of GMCs</param_type>
            <param_value>0.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.60</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
            <estimate_desc>CIs for the ratio were back transformations of the CIs based on the Student t distribution for the mean difference of the logarithmically transformed assay results.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 3. The primary null hypothesis was: the log of the GMC in the group receiving 13vPnC and TIV concomitantly, minus the log of the GMC in the group receiving 13vPnC alone (1 month after TIV) &lt;= -0.693.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The criterion upon which to declare non-inferiority was the lower bound of the 2-sided, 95% CI for the geometric mean ratio greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio of GMCs</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
            <estimate_desc>CIs for the ratio were back transformations of the CIs based on the Student t distribution for the mean difference of the logarithmically transformed assay results.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 4. The primary null hypothesis was: the log of the GMC in the group receiving 13vPnC and TIV concomitantly, minus the log of the GMC in the group receiving 13vPnC alone (1 month after TIV) &lt;= -0.693.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The criterion upon which to declare non-inferiority was the lower bound of the 2-sided, 95% CI for the geometric mean ratio greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio of GMCs</param_type>
            <param_value>0.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.51</ci_lower_limit>
            <ci_upper_limit>0.87</ci_upper_limit>
            <estimate_desc>CIs for the ratio were back transformations of the CIs based on the Student t distribution for the mean difference of the logarithmically transformed assay results.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 5. The primary null hypothesis was: the log of the GMC in the group receiving 13vPnC and TIV concomitantly, minus the log of the GMC in the group receiving 13vPnC alone (1 month after TIV) &lt;= -0.693.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The criterion upon which to declare non-inferiority was the lower bound of the 2-sided, 95% CI for the geometric mean ratio greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio of GMCs</param_type>
            <param_value>0.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>0.86</ci_upper_limit>
            <estimate_desc>CIs for the ratio were back transformations of the CIs based on the Student t distribution for the mean difference of the logarithmically transformed assay results.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 6A. The primary null hypothesis was: the log of the GMC in the group receiving 13vPnC and TIV concomitantly, minus the log of the GMC in the group receiving 13vPnC alone (1 month after TIV) &lt;= -0.693.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The criterion upon which to declare non-inferiority was the lower bound of the 2-sided, 95% CI for the geometric mean ratio greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio of GMCs</param_type>
            <param_value>0.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>0.94</ci_upper_limit>
            <estimate_desc>CIs for the ratio were back transformations of the CIs based on the Student t distribution for the mean difference of the logarithmically transformed assay results.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 6B. The primary null hypothesis was: the log of the GMC in the group receiving 13vPnC and TIV concomitantly, minus the log of the GMC in the group receiving 13vPnC alone (1 month after TIV) &lt;= -0.693.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The criterion upon which to declare non-inferiority was the lower bound of the 2-sided, 95% CI for the geometric mean ratio greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio of GMCs</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>1.25</ci_upper_limit>
            <estimate_desc>CIs for the ratio were back transformations of the CIs based on the Student t distribution for the mean difference of the logarithmically transformed assay results.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 7F. The primary null hypothesis was: the log of the GMC in the group receiving 13vPnC and TIV concomitantly, minus the log of the GMC in the group receiving 13vPnC alone (1 month after TIV) &lt;= -0.693.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The criterion upon which to declare non-inferiority was the lower bound of the 2-sided, 95% CI for the geometric mean ratio greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio of GMCs</param_type>
            <param_value>0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
            <estimate_desc>CIs for the ratio were back transformations of the CIs based on the Student t distribution for the mean difference of the logarithmically transformed assay results.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 9V. The primary null hypothesis was: the log of the GMC in the group receiving 13vPnC and TIV concomitantly, minus the log of the GMC in the group receiving 13vPnC alone (1 month after TIV) &lt;= -0.693.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The criterion upon which to declare non-inferiority was the lower bound of the 2-sided, 95% CI for the geometric mean ratio greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio of GMCs</param_type>
            <param_value>0.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
            <estimate_desc>CIs for the ratio were back transformations of the CIs based on the Student t distribution for the mean difference of the logarithmically transformed assay results.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 14. The primary null hypothesis was: the log of the GMC in the group receiving 13vPnC and TIV concomitantly, minus the log of the GMC in the group receiving 13vPnC alone (1 month after TIV) &lt;= -0.693.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The criterion upon which to declare non-inferiority was the lower bound of the 2-sided, 95% CI for the geometric mean ratio greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio of GMCs</param_type>
            <param_value>0.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.53</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
            <estimate_desc>CIs for the ratio were back transformations of the CIs based on the Student t distribution for the mean difference of the logarithmically transformed assay results.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 18C. The primary null hypothesis was: the log of the GMC in the group receiving 13vPnC and TIV concomitantly, minus the log of the GMC in the group receiving 13vPnC alone (1 month after TIV) &lt;= -0.693.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The criterion upon which to declare non-inferiority was the lower bound of the 2-sided, 95% CI for the geometric mean ratio greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio of GMCs</param_type>
            <param_value>0.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
            <estimate_desc>CIs for the ratio were back transformations of the CIs based on the Student t distribution for the mean difference of the logarithmically transformed assay results.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 19A. The primary null hypothesis was: the log of the GMC in the group receiving 13vPnC and TIV concomitantly, minus the log of the GMC in the group receiving 13vPnC alone (1 month after TIV) &lt;= -0.693.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The criterion upon which to declare non-inferiority was the lower bound of the 2-sided, 95% CI for the geometric mean ratio greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio of GMCs</param_type>
            <param_value>0.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.56</ci_lower_limit>
            <ci_upper_limit>0.87</ci_upper_limit>
            <estimate_desc>CIs for the ratio were back transformations of the CIs based on the Student t distribution for the mean difference of the logarithmically transformed assay results.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 19F. The primary null hypothesis was: the log of the GMC in the group receiving 13vPnC and TIV concomitantly, minus the log of the GMC in the group receiving 13vPnC alone (1 month after TIV) &lt;= -0.693.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The criterion upon which to declare non-inferiority was the lower bound of the 2-sided, 95% CI for the geometric mean ratio greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio of GMCs</param_type>
            <param_value>0.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.49</ci_lower_limit>
            <ci_upper_limit>0.85</ci_upper_limit>
            <estimate_desc>CIs for the ratio were back transformations of the CIs based on the Student t distribution for the mean difference of the logarithmically transformed assay results.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 23F. The primary null hypothesis was: the log of the GMC in the group receiving 13vPnC and TIV concomitantly, minus the log of the GMC in the group receiving 13vPnC alone (1 month after TIV) &lt;= -0.693.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The criterion upon which to declare non-inferiority was the lower bound of the 2-sided, 95% CI for the geometric mean ratio greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio of GMCs</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.71</ci_lower_limit>
            <ci_upper_limit>1.27</ci_upper_limit>
            <estimate_desc>CIs for the ratio were back transformations of the CIs based on the Student t distribution for the mean difference of the logarithmically transformed assay results.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants With Pre-specified Local Reactions</title>
        <description>Local reactions were reported using an electronic diary. Pain was scaled as Any; Mild (awareness but easily tolerated); Moderate (discomfort enough to interfere with usual activity) and Severe (incapacitating the usual activity). Redness and swelling were scaled as Any; Mild (2.5 cm to 5.0 cm); Moderate (5.1 to 10.0 cm)and Severe (&gt; 10.0 cm). Limitation in arm movement were scaled as Any; Mild (some limitation); Moderate (unable to move above head but able to move above shoulder) and Severe (unable to move above shoulder).</description>
        <time_frame>Days 1 through 14 after 13vPnC vaccination</time_frame>
        <population>Safety population: included all participants who received at least 1 dose of study vaccine. n=number of participants at each timepoint, in each group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC+TIV</title>
            <description>Single 0.5 milliliter (mL) 13-valent pneumococcal conjugate vaccine (13vPnC) and a single 0.5 mL trivalent inactivated influenza vaccine (TIV), administered intramuscularly (IM).</description>
          </group>
          <group group_id="O2">
            <title>13vPnC</title>
            <description>Single 0.5 mL 13vPnC (administered 1 month after single 0.5 mL 13vPnC placebo vaccine and a single 0.5 mL TIV, IM).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Pre-specified Local Reactions</title>
          <description>Local reactions were reported using an electronic diary. Pain was scaled as Any; Mild (awareness but easily tolerated); Moderate (discomfort enough to interfere with usual activity) and Severe (incapacitating the usual activity). Redness and swelling were scaled as Any; Mild (2.5 cm to 5.0 cm); Moderate (5.1 to 10.0 cm)and Severe (&gt; 10.0 cm). Limitation in arm movement were scaled as Any; Mild (some limitation); Moderate (unable to move above head but able to move above shoulder) and Severe (unable to move above shoulder).</description>
          <population>Safety population: included all participants who received at least 1 dose of study vaccine. n=number of participants at each timepoint, in each group respectively.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="577"/>
                <count group_id="O2" value="558"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Redness: Any (n= 440, 432)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.6" lower_limit="-0.4" upper_limit="9.0"/>
                    <measurement group_id="O2" value="12.3" lower_limit="-0.4" upper_limit="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Mild (n= 438, 432)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.4" lower_limit="0.3" upper_limit="9.1"/>
                    <measurement group_id="O2" value="9.7" lower_limit="0.3" upper_limit="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Moderate (n= 433, 424)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" lower_limit="-3.4" upper_limit="3.1"/>
                    <measurement group_id="O2" value="6.1" lower_limit="-3.4" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Severe (n= 429, 420)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" lower_limit="-1.8" upper_limit="1.2"/>
                    <measurement group_id="O2" value="1.0" lower_limit="-1.8" upper_limit="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Any (n= 441, 431)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8" lower_limit="-0.7" upper_limit="8.0"/>
                    <measurement group_id="O2" value="10.2" lower_limit="-0.7" upper_limit="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Mild (n= 440, 430)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8" lower_limit="-0.3" upper_limit="7.7"/>
                    <measurement group_id="O2" value="8.1" lower_limit="-0.3" upper_limit="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Moderate (n= 432, 423)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" lower_limit="-3.7" upper_limit="2.1"/>
                    <measurement group_id="O2" value="5.0" lower_limit="-3.7" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Severe (n= 428, 420)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" lower_limit="-0.7" upper_limit="1.3"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-0.7" upper_limit="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Any (n= 480, 470)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0" lower_limit="-9.7" upper_limit="3.0"/>
                    <measurement group_id="O2" value="43.4" lower_limit="-9.7" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Mild (n= 470, 462)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.3" lower_limit="-9.8" upper_limit="2.6"/>
                    <measurement group_id="O2" value="37.9" lower_limit="-9.8" upper_limit="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Moderate (n= 447, 442)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8" lower_limit="-9.9" upper_limit="0.1"/>
                    <measurement group_id="O2" value="19.7" lower_limit="-9.9" upper_limit="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Severe (n= 429, 421)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="-3.4" upper_limit="0.8"/>
                    <measurement group_id="O2" value="2.6" lower_limit="-3.4" upper_limit="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limitation of arm movement: Any (n= 445, 432)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.9" lower_limit="-5.6" upper_limit="3.8"/>
                    <measurement group_id="O2" value="14.8" lower_limit="-5.6" upper_limit="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limitation of arm movement: Mild (n= 444, 432)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.1" lower_limit="-4.9" upper_limit="4.2"/>
                    <measurement group_id="O2" value="13.4" lower_limit="-4.9" upper_limit="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limitation of arm movement:Moderate (n= 430, 420)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="-1.2" upper_limit="2.2"/>
                    <measurement group_id="O2" value="1.0" lower_limit="-1.2" upper_limit="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limitation of arm movement: Severe (n= 429, 420)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="-1.4" upper_limit="2.4"/>
                    <measurement group_id="O2" value="1.4" lower_limit="-1.4" upper_limit="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any local reaction (n= 488, 470)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.9" lower_limit="-6.0" upper_limit="6.7"/>
                    <measurement group_id="O2" value="46.6" lower_limit="-6.0" upper_limit="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants With Pre-specified Systemic Events</title>
        <description>Systemic events (Any fever &gt;= 38 degrees Celsius [C]), fatigue, headache, chills, rash, vomiting, decreased appetite, new muscle pain, any aggravated muscle pain, new joint pain or any aggravated joint pain. Participants may be presented in more than one category.</description>
        <time_frame>Days 1 through 14 after 13vPnC vaccination</time_frame>
        <population>Safety population: included all participants who received at least 1 dose of study vaccine. n=number of participants at each timepoint, in each group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC+TIV</title>
            <description>Single 0.5 milliliter (mL) 13-valent pneumococcal conjugate vaccine (13vPnC) and a single 0.5 mL trivalent inactivated influenza vaccine (TIV), administered intramuscularly (IM).</description>
          </group>
          <group group_id="O2">
            <title>13vPnC</title>
            <description>Single 0.5 mL 13vPnC (administered 1 month after single 0.5 mL 13vPnC placebo vaccine and a single 0.5 mL TIV, IM).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Pre-specified Systemic Events</title>
          <description>Systemic events (Any fever &gt;= 38 degrees Celsius [C]), fatigue, headache, chills, rash, vomiting, decreased appetite, new muscle pain, any aggravated muscle pain, new joint pain or any aggravated joint pain. Participants may be presented in more than one category.</description>
          <population>Safety population: included all participants who received at least 1 dose of study vaccine. n=number of participants at each timepoint, in each group respectively.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="577"/>
                <count group_id="O2" value="558"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever &gt;=38 degreesC but &lt;38.5 degreesC (n=434,423)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="-2.5" upper_limit="2.3"/>
                    <measurement group_id="O2" value="3.1" lower_limit="-2.5" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;=38.5 degreesC but &lt;39 degreesC (n=430,421)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="-1.2" upper_limit="2.2"/>
                    <measurement group_id="O2" value="1.0" lower_limit="-1.2" upper_limit="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;=39degreesC but &lt;=40.0degreesC (n=428,420)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-0.9" upper_limit="0.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-0.9" upper_limit="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;40.0 degrees C (n= 429, 422)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="-0.8" upper_limit="2.4"/>
                    <measurement group_id="O2" value="0.7" lower_limit="-0.8" upper_limit="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue (n= 476, 456)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.4" lower_limit="2.8" upper_limit="14.9"/>
                    <measurement group_id="O2" value="28.5" lower_limit="2.8" upper_limit="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (n= 472, 449)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.6" lower_limit="2.1" upper_limit="13.8"/>
                    <measurement group_id="O2" value="24.7" lower_limit="2.1" upper_limit="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills (n= 443, 429)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8" lower_limit="0.4" upper_limit="9.0"/>
                    <measurement group_id="O2" value="9.1" lower_limit="0.4" upper_limit="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash (n= 433, 427)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" lower_limit="-3.3" upper_limit="3.6"/>
                    <measurement group_id="O2" value="6.8" lower_limit="-3.3" upper_limit="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting (n= 432, 424)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="-0.7" upper_limit="3.6"/>
                    <measurement group_id="O2" value="1.7" lower_limit="-0.7" upper_limit="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased appetite (n= 450, 434)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.9" lower_limit="1.0" upper_limit="10.2"/>
                    <measurement group_id="O2" value="11.3" lower_limit="1.0" upper_limit="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New muscle pain (n= 468, 448)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.9" lower_limit="-2.2" upper_limit="9.1"/>
                    <measurement group_id="O2" value="23.4" lower_limit="-2.2" upper_limit="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any aggravated muscle pain (n= 454, 439)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.7" lower_limit="-1.2" upper_limit="8.7"/>
                    <measurement group_id="O2" value="15.0" lower_limit="-1.2" upper_limit="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New joint pain (n= 452, 435)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.2" lower_limit="0.1" upper_limit="9.2"/>
                    <measurement group_id="O2" value="11.5" lower_limit="0.1" upper_limit="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any aggravated joint pain (n= 452, 428)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.7" lower_limit="2.7" upper_limit="11.4"/>
                    <measurement group_id="O2" value="8.6" lower_limit="2.7" upper_limit="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any systemic event (n= 510, 488)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.2" lower_limit="5.4" upper_limit="17.8"/>
                    <measurement group_id="O2" value="48.6" lower_limit="5.4" upper_limit="17.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>13vPnC Comparisons: Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMT)</title>
        <description>Pneumococcal OPA GMTs for 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of a subset of participants using a microcolony OPA (mcOPA) assay.</description>
        <time_frame>1 month after 13vPnC vaccination</time_frame>
        <population>Evaluable immunogenicity population: had participants who adhered to protocol requirements, had valid and determinate assay results, and had no major protocol violations. n= number of participants with a determinate OPA antibody titer to the given serotype.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC+TIV</title>
            <description>Single 0.5 milliliter (mL) 13-valent pneumococcal conjugate vaccine (13vPnC) and a single 0.5 mL trivalent inactivated influenza vaccine (TIV), administered intramuscularly (IM).</description>
          </group>
          <group group_id="O2">
            <title>13vPnC</title>
            <description>Single 0.5 mL 13vPnC (administered 1 month after single 0.5 mL 13vPnC placebo vaccine and a single 0.5 mL TIV, IM).</description>
          </group>
        </group_list>
        <measure>
          <title>13vPnC Comparisons: Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMT)</title>
          <description>Pneumococcal OPA GMTs for 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of a subset of participants using a microcolony OPA (mcOPA) assay.</description>
          <population>Evaluable immunogenicity population: had participants who adhered to protocol requirements, had valid and determinate assay results, and had no major protocol violations. n= number of participants with a determinate OPA antibody titer to the given serotype.</population>
          <units>Geometric mean titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="259"/>
                <count group_id="O2" value="255"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1 (n= 256, 255)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88" lower_limit="71.1" upper_limit="108.3"/>
                    <measurement group_id="O2" value="95" lower_limit="76.8" upper_limit="117.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3 (n= 235, 237)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46" lower_limit="37.9" upper_limit="56.1"/>
                    <measurement group_id="O2" value="51" lower_limit="41.7" upper_limit="61.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4 (n= 247, 245)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="997" lower_limit="766.3" upper_limit="1296.0"/>
                    <measurement group_id="O2" value="1486" lower_limit="1174.7" upper_limit="1879.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5 (n= 245, 234)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124" lower_limit="97.3" upper_limit="158.8"/>
                    <measurement group_id="O2" value="112" lower_limit="85.1" upper_limit="146.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A (n= 250, 252)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1220" lower_limit="950.6" upper_limit="1566.7"/>
                    <measurement group_id="O2" value="1597" lower_limit="1256.4" upper_limit="2030.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B (n= 259, 248)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1564" lower_limit="1239.4" upper_limit="1973.9"/>
                    <measurement group_id="O2" value="2017" lower_limit="1564.8" upper_limit="2599.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F (n= 246, 248)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="607" lower_limit="444.2" upper_limit="828.8"/>
                    <measurement group_id="O2" value="835" lower_limit="619.9" upper_limit="1123.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V (n= 247, 242)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="477" lower_limit="348.5" upper_limit="652.7"/>
                    <measurement group_id="O2" value="723" lower_limit="528.1" upper_limit="988.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14 (n= 247, 236)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="975" lower_limit="781.6" upper_limit="1215.5"/>
                    <measurement group_id="O2" value="1088" lower_limit="858.4" upper_limit="1379.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C (n= 250, 244)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1158" lower_limit="909.5" upper_limit="1475.1"/>
                    <measurement group_id="O2" value="1415" lower_limit="1122.0" upper_limit="1785.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A (n= 251, 247)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="445" lower_limit="365.1" upper_limit="542.1"/>
                    <measurement group_id="O2" value="539" lower_limit="427.8" upper_limit="679.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F (n= 247, 242)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="378" lower_limit="295.8" upper_limit="483.8"/>
                    <measurement group_id="O2" value="467" lower_limit="360.7" upper_limit="605.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F (n= 252, 242)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245" lower_limit="180.2" upper_limit="332.4"/>
                    <measurement group_id="O2" value="295" lower_limit="217.9" upper_limit="400.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 1. The primary null hypothesis was: the log of the GMT in the group receiving 13vPnC + TIV minus the log of the GMT in the group receiving 13vPnC alone (1 month after TIV) &lt;= -0.693.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The criterion upon which to declare non-inferiority was if the lower limit of the 2-sided 95%CI for the GMT ratios, (13vPnC+TIV relative to 13vPnC administered 1 month after TIV+placebo) was greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>1.24</ci_upper_limit>
            <estimate_desc>2-sided 95% CIs for the GMT ratio were calculated by back transformations of the 95% CIs based on the Student t distribution for the mean difference of the logarithmically transformed assay results.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 3. The primary null hypothesis was: the log of the GMT in the group receiving 13vPnC + TIV minus the log of the GMT in the group receiving 13vPnC alone (1 month after TIV) &lt;= -0.693.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The criterion upon which to declare non-inferiority was if the lower limit of the 2-sided 95%CI for the GMT ratios, (13vPnC+TIV relative to 13vPnC administered 1 month after TIV+placebo) was greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>1.20</ci_upper_limit>
            <estimate_desc>2-sided 95% CIs for the GMT ratio were calculated by back transformations of the 95% CIs based on the Student t distribution for the mean difference of the logarithmically transformed assay results.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 4. The primary null hypothesis was: the log of the GMT in the group receiving 13vPnC + TIV minus the log of the GMT in the group receiving 13vPnC alone (1 month after TIV) &lt;= -0.693.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The criterion upon which to declare non-inferiority was if the lower limit of the 2-sided 95%CI for the GMT ratios, (13vPnC+TIV relative to 13vPnC administered 1 month after TIV+placebo) was greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.47</ci_lower_limit>
            <ci_upper_limit>0.95</ci_upper_limit>
            <estimate_desc>2-sided 95% CIs for the GMT ratio were calculated by back transformations of the 95% CIs based on the Student t distribution for the mean difference of the logarithmically transformed assay results.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 5. The primary null hypothesis was: the log of the GMT in the group receiving 13vPnC + TIV minus the log of the GMT in the group receiving 13vPnC alone (1 month after TIV) &lt;= -0.693.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The criterion upon which to declare non-inferiority was if the lower limit of the 2-sided 95%CI for the GMT ratios, (13vPnC+TIV relative to 13vPnC administered 1 month after TIV+placebo) was greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>1.60</ci_upper_limit>
            <estimate_desc>2-sided 95% CIs for the GMT ratio were calculated by back transformations of the 95% CIs based on the Student t distribution for the mean difference of the logarithmically transformed assay results.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 6A. The primary null hypothesis was: the log of the GMT in the group receiving 13vPnC + TIV minus the log of the GMT in the group receiving 13vPnC alone (1 month after TIV) &lt;= -0.693.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The criterion upon which to declare non-inferiority was if the lower limit of the 2-sided 95%CI for the GMT ratios, (13vPnC+TIV relative to 13vPnC administered 1 month after TIV+placebo) was greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.54</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
            <estimate_desc>2-sided 95% CIs for the GMT ratio were calculated by back transformations of the 95% CIs based on the Student t distribution for the mean difference of the logarithmically transformed assay results.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 6B. The primary null hypothesis was: the log of the GMT in the group receiving 13vPnC + TIV minus the log of the GMT in the group receiving 13vPnC alone (1 month after TIV) &lt;= -0.693.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The criterion upon which to declare non-inferiority was if the lower limit of the 2-sided 95%CI for the GMT ratios, (13vPnC+TIV relative to 13vPnC administered 1 month after TIV+placebo) was greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
            <estimate_desc>2-sided 95% CIs for the GMT ratio were calculated by back transformations of the 95% CIs based on the Student t distribution for the mean difference of the logarithmically transformed assay results.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 7F. The primary null hypothesis was: the log of the GMT in the group receiving 13vPnC + TIV minus the log of the GMT in the group receiving 13vPnC alone (1 month after TIV) &lt;= -0.693.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The criterion upon which to declare non-inferiority was if the lower limit of the 2-sided 95%CI for the GMT ratios, (13vPnC+TIV relative to 13vPnC administered 1 month after TIV+placebo) was greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.47</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
            <estimate_desc>2-sided 95% CIs for the GMT ratio were calculated by back transformations of the 95% CIs based on the Student t distribution for the mean difference of the logarithmically transformed assay results.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 9V. The primary null hypothesis was: the log of the GMT in the group receiving 13vPnC + TIV minus the log of the GMT in the group receiving 13vPnC alone (1 month after TIV) &lt;= -0.693.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The criterion upon which to declare non-inferiority was if the lower limit of the 2-sided 95%CI for the GMT ratios, (13vPnC+TIV relative to 13vPnC administered 1 month after TIV+placebo) was greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.42</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
            <estimate_desc>2-sided 95% CIs for the GMT ratio were calculated by back transformations of the 95% CIs based on the Student t distribution for the mean difference of the logarithmically transformed assay results.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 14. The primary null hypothesis was: the log of the GMT in the group receiving 13vPnC + TIV minus the log of the GMT in the group receiving 13vPnC alone (1 month after TIV) &lt;= -0.693.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The criterion upon which to declare non-inferiority was if the lower limit of the 2-sided 95%CI for the GMT ratios, (13vPnC+TIV relative to 13vPnC administered 1 month after TIV+placebo) was greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>1.24</ci_upper_limit>
            <estimate_desc>2-sided 95% CIs for the GMT ratio were calculated by back transformations of the 95% CIs based on the Student t distribution for the mean difference of the logarithmically transformed assay results.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 18C. The primary null hypothesis was: the log of the GMT in the group receiving 13vPnC + TIV minus the log of the GMT in the group receiving 13vPnC alone (1 month after TIV) &lt;= -0.693.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The criterion upon which to declare non-inferiority was if the lower limit of the 2-sided 95%CI for the GMT ratios, (13vPnC+TIV relative to 13vPnC administered 1 month after TIV+placebo) was greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
            <estimate_desc>2-sided 95% CIs for the GMT ratio were calculated by back transformations of the 95% CIs based on the Student t distribution for the mean difference of the logarithmically transformed assay results.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 19A. The primary null hypothesis was: the log of the GMT in the group receiving 13vPnC + TIV minus the log of the GMT in the group receiving 13vPnC alone (1 month after TIV) &lt;= -0.693.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The criterion upon which to declare non-inferiority was if the lower limit of the 2-sided 95%CI for the GMT ratios, (13vPnC+TIV relative to 13vPnC administered 1 month after TIV+placebo) was greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
            <estimate_desc>2-sided 95% CIs for the GMT ratio were calculated by back transformations of the 95% CIs based on the Student t distribution for the mean difference of the logarithmically transformed assay results.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 19F. The primary null hypothesis was: the log of the GMT in the group receiving 13vPnC + TIV minus the log of the GMT in the group receiving 13vPnC alone (1 month after TIV) &lt;= -0.693.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The criterion upon which to declare non-inferiority was if the lower limit of the 2-sided 95%CI for the GMT ratios, (13vPnC+TIV relative to 13vPnC administered 1 month after TIV+placebo) was greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.57</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
            <estimate_desc>2-sided 95% CIs for the GMT ratio were calculated by back transformations of the 95% CIs based on the Student t distribution for the mean difference of the logarithmically transformed assay results.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 23F. The primary null hypothesis was: the log of the GMT in the group receiving 13vPnC + TIV minus the log of the GMT in the group receiving 13vPnC alone (1 month after TIV) &lt;= -0.693.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The criterion upon which to declare non-inferiority was if the lower limit of the 2-sided 95%CI for the GMT ratios, (13vPnC+TIV relative to 13vPnC administered 1 month after TIV+placebo) was greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.54</ci_lower_limit>
            <ci_upper_limit>1.27</ci_upper_limit>
            <estimate_desc>2-sided 95% CIs for the GMT ratio were calculated by back transformations of the 95% CIs based on the Student t distribution for the mean difference of the logarithmically transformed assay results.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs/SAEs recorded from signing of informed consent form to completion of study (Visit 3).Participants recorded in the e-diary their local reactions,systemic events &amp; use of antipyretic &amp; pain medication (Day 1-Day 14 after study vaccine administration).</time_frame>
      <desc>SAEs were grouped by organ system, with number and frequency of events summarized. Non-serious AEs were summarized in a similar manner and included solicited AEs collected in the e-diary (systematic assessment) and unsolicited events collected on the case report form at each visit (non-systematic assessment).</desc>
      <group_list>
        <group group_id="E1">
          <title>13vPnC+TIV</title>
          <description>Single 0.5 mL 13vPnC and a single 0.5 mL TIV, administered IM.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Single 0.5 mL 13vPnC placebo vaccine (administered 1 month after a single 0.5 mL 13vPnC and a single 0.5 mL TIV, IM [13vPnC + TIV]).</description>
        </group>
        <group group_id="E3">
          <title>Placebo+TIV</title>
          <description>Single 0.5 mL 13vPnC placebo vaccine and a single 0.5 mL TIV, administered IM.</description>
        </group>
        <group group_id="E4">
          <title>13vPnC</title>
          <description>Single 0.5 mL 13vPnC (administered 1 month after single 0.5 mL 13vPnC placebo vaccine and a single 0.5 mL TIV, IM [Placebo + TIV]).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Sternal fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Endoscopy small intestine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Electrocardiogram ST segment elevation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cardiac pacemaker insertion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="307" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="194" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="256" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="237" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness unilateral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Cheilitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title vocab="Systemic events">Fever ≥ 38 degrees C but &lt; 38.5 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="434"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="398"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fever ≥ 38.5 degrees C but &lt; 39 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="430"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="394"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="433"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fever ≥ 39 degrees C but ≤ 40.0 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="394"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fever &gt; 40.0 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="438"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fatigue</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="178" subjects_at_risk="476"/>
                <counts group_id="E2" subjects_affected="120" subjects_at_risk="434"/>
                <counts group_id="E3" subjects_affected="154" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="130" subjects_at_risk="456"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Headache</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="154" subjects_at_risk="472"/>
                <counts group_id="E2" subjects_affected="114" subjects_at_risk="436"/>
                <counts group_id="E3" subjects_affected="139" subjects_at_risk="468"/>
                <counts group_id="E4" subjects_affected="111" subjects_at_risk="449"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Chills</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="404"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="429"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Rash</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="397"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="436"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Vomiting</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="398"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="437"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Decreased appetite</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="450"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="415"/>
                <counts group_id="E3" subjects_affected="66" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="49" subjects_at_risk="434"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">New muscle pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="126" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="413"/>
                <counts group_id="E3" subjects_affected="76" subjects_at_risk="456"/>
                <counts group_id="E4" subjects_affected="105" subjects_at_risk="448"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Any aggravated muscle pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="454"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="63" subjects_at_risk="449"/>
                <counts group_id="E4" subjects_affected="66" subjects_at_risk="439"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">New joint pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="59" subjects_at_risk="451"/>
                <counts group_id="E4" subjects_affected="50" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Any aggravated joint pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="58" subjects_at_risk="447"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Injection site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Sensation of foreign body</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Enterovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Eyelid infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Fungal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Traumatic haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Corneal abrasion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Total lung capacity decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Cardiac murmur</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Osteitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Tenosynovitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Cervicobrachial syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Restless legs syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Vertebrobasilar insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Post-traumatic stress disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Nephrocalcinosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Urge incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Bartholin's cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Fibrocystic breast disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Diaphragmatic hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title vocab="Local reactions">Redness (any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Redness (any) = present at site of vaccination</description>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="433"/>
                <counts group_id="E4" subjects_affected="53" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Redness (mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Redness (mild) = 2.5 to 5.0 cm</description>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="433"/>
                <counts group_id="E4" subjects_affected="42" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Redness (moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Redness (moderate) = 5.1 to 10.0 cm</description>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Redness (severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Redness (severe) = &gt;10.0 cm</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Swelling (any) = present at site of vaccination</description>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="394"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="435"/>
                <counts group_id="E4" subjects_affected="44" subjects_at_risk="431"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Swelling (mild) = 2.5 to 5.0 cm</description>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="440"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="394"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="434"/>
                <counts group_id="E4" subjects_affected="35" subjects_at_risk="430"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Swelling (moderate) = 5.1 to 10.0 cm</description>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="433"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Swelling (severe) = &gt;10.0 cm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Pain (any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Pain (any) = present at site of vaccination</description>
                <counts group_id="E1" subjects_affected="192" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="411"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="204" subjects_at_risk="470"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Pain (mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Pain (mild) = awareness of symptoms but easily tolerated</description>
                <counts group_id="E1" subjects_affected="161" subjects_at_risk="470"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="175" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Pain (moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Pain (moderate) = discomfort enough to cause interference with usual activity</description>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="447"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="397"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="437"/>
                <counts group_id="E4" subjects_affected="87" subjects_at_risk="442"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Pain (severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Pain (severe) = unable to move above shoulder</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Limitation of arm movement (any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Limitation of arm movement (any) = present</description>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="445"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="397"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="64" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Limitation of arm movement (mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Limitation of arm movement (mild) = some limitation</description>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="397"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="58" subjects_at_risk="432"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Limitation of arm movement (moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Limitation of arm movement (moderate) = unable to move above head but able to move above shoulder</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="430"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Limitation of arm movement (severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Limitation of arm movement (severe) = unable to move above shoulder</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="392"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="420"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Dermatitis bullous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Dental prosthesis user</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

